key: cord-0696692-890adcsn
authors: Benderra, Marc-Antoine; Ferrier, Clement; Buob, David; Gligorov, Joseph; Kerrou, Khaldoun
title: Neglected giant benign phyllode tumor of the breast
date: 2022-05-18
journal: Eur J Nucl Med Mol Imaging
DOI: 10.1007/s00259-022-05840-7
sha: c82dea620ab0397edaa447638c81f1d5575f079f
doc_id: 696692
cord_uid: 890adcsn

nan

appeared more than a year earlier. The ulcerating mass measured more than 30 cm. The patient was delayed in consulting due to the COVID-19 pandemic. On admission, she had an Eastern Cooperative Oncology Group performance-status (ECOG-PS) score of 4, albuminemia at 8 g/dl with a high level of C-reactive protein. 18 for staging a suspected malignant breast cancer. The maximum standardized uptake value (SUV max ) measured in the right breast tumor was 7.4 (volume-rendering images of 18F-FDG PET (A), CT (B), and fused PET/CT (C)). The pathologic examinations of the biopsies were benign. In the other breast, the 18F-FDG PET identified a 23-mm lesion whose biopsy found an invasive carcinoma ER-positive/ Her2-positive. Although the anesthetic risk was high, it was decided to perform the surgery. A right mastectomy and left breast conservative surgery with sentinel-lymphnode resection were performed in the same time. The final pathologic examination confirmed a benign phyllode tumor of 36 cm on the right breast and an invasive Her2-positive breast cancer on the left. For the left breast, radiotherapy and adjuvant chemotherapy with APT [1] were performed then endocrine therapy. After the surgery, the patient quickly recovered an ECOG-PS of 0. This case highlights the fact that surgery remains the standard treatment for low-grade phyllode tumors.

Ethics approval and informed consent All procedures performed involving the human participant were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from the patient.

The authors declare no competing interests.

Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer